199 related articles for article (PubMed ID: 30580105)
1. The management and outcomes of patients with myelodysplastic syndrome with persistent severe thrombocytopenia: An observational single centre registry study.
Vijenthira A; Premkumar D; Callum J; Lin Y; Wells RA; Chodirker L; Lenis M; Mamedov A; Buckstein R
Leuk Res; 2019 Jan; 76():76-81. PubMed ID: 30580105
[TBL] [Abstract][Full Text] [Related]
2. Platelet transfusions and predictors of bleeding in patients with myelodysplastic syndromes.
Mo A; Wood E; Shortt J; Hu E; McQuilten Z
Eur J Haematol; 2023 Oct; 111(4):592-600. PubMed ID: 37452616
[TBL] [Abstract][Full Text] [Related]
3. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation.
Estcourt L; Stanworth S; Doree C; Hopewell S; Murphy MF; Tinmouth A; Heddle N
Cochrane Database Syst Rev; 2012 May; (5):CD004269. PubMed ID: 22592695
[TBL] [Abstract][Full Text] [Related]
4. Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders.
Wardrop D; Estcourt LJ; Brunskill SJ; Doree C; Trivella M; Stanworth S; Murphy MF
Cochrane Database Syst Rev; 2013 Jul; (7):CD009733. PubMed ID: 23897323
[TBL] [Abstract][Full Text] [Related]
5. Use of platelet transfusions and tranexamic acid in patients with myelodysplastic syndromes: A clinical practice survey.
Mo A; Weinkove R; Wood EM; Shortt J; Johnston A; McQuilten ZK;
Eur J Haematol; 2024 Apr; 112(4):621-626. PubMed ID: 38123137
[TBL] [Abstract][Full Text] [Related]
6. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
Oliva EN; Alati C; Santini V; Poloni A; Molteni A; Niscola P; Salvi F; Sanpaolo G; Balleari E; Germing U; Fenaux P; Stamatoullas A; Palumbo GA; Salutari P; Impera S; Avanzini P; Cortelezzi A; Liberati AM; Carluccio P; Buccisano F; Voso MT; Mancini S; Kulasekararaj A; Morabito F; Bocchia M; Cufari P; Spiriti MA; Santacaterina I; D'Errigo MG; Bova I; Zini G; Latagliata R
Lancet Haematol; 2017 Mar; 4(3):e127-e136. PubMed ID: 28162984
[TBL] [Abstract][Full Text] [Related]
7. Lack of efficacy of tranexamic acid in thrombocytopenic bleeding.
Fricke W; Alling D; Kimball J; Griffith P; Klein H
Transfusion; 1991 May; 31(4):345-8. PubMed ID: 1823527
[TBL] [Abstract][Full Text] [Related]
8. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
Mittelman M; Platzbecker U; Afanasyev B; Grosicki S; Wong RSM; Anagnostopoulos A; Brenner B; Denzlinger C; Rossi G; Nagler A; Garcia-Delgado R; Portella MSO; Zhu Z; Selleslag D
Lancet Haematol; 2018 Jan; 5(1):e34-e43. PubMed ID: 29241762
[TBL] [Abstract][Full Text] [Related]
9. Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies.
Li W; Morrone K; Kambhampati S; Will B; Steidl U; Verma A
Leukemia; 2016 Mar; 30(3):536-44. PubMed ID: 26500138
[TBL] [Abstract][Full Text] [Related]
10. New strategies for the optimal use of platelet transfusions.
Blajchman MA; Slichter SJ; Heddle NM; Murphy MF
Hematology Am Soc Hematol Educ Program; 2008; ():198-204. PubMed ID: 19074082
[TBL] [Abstract][Full Text] [Related]
11. Prediction of bleeding and prophylactic platelet transfusions in cancer patients with thrombocytopenia.
Vinholt PJ; Alnor A; Nybo M; Hvas AM
Platelets; 2016 Sep; 27(6):547-54. PubMed ID: 27025360
[TBL] [Abstract][Full Text] [Related]
12. Platelet transfusion and tranexamic acid to prevent bleeding in outpatients with a hematological disease: A Dutch nationwide survey.
Cornelissen LL; Caram-Deelder C; Meier RT; Zwaginga JJ; Evers D;
Eur J Haematol; 2021 Mar; 106(3):362-370. PubMed ID: 33226659
[TBL] [Abstract][Full Text] [Related]
13. Platelet Transfusion Practices in the ICU: Data From a Large Transfusion Registry.
Ning S; Barty R; Liu Y; Heddle NM; Rochwerg B; Arnold DM
Chest; 2016 Sep; 150(3):516-23. PubMed ID: 27102183
[TBL] [Abstract][Full Text] [Related]
14. Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications.
Al Ameri A; Jabbour E; Garcia-Manero G; O'Brien S; Faderl S; Ravandi F; Shan J; Pierce S; Cortes J; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2011 Apr; 11(2):237-41. PubMed ID: 21575929
[TBL] [Abstract][Full Text] [Related]
15. Danazol for the treatment of thrombocytopenia in patients with myelodysplastic syndrome.
Chan G; DiVenuti G; Miller K
Am J Hematol; 2002 Nov; 71(3):166-71. PubMed ID: 12410570
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome.
Gonzalez-Porras JR; Cordoba I; Such E; Nomdedeu B; Vallespi T; Carbonell F; Luño E; Ardanaz M; Ramos F; Pedro C; Gomez V; de Paz R; Sanchez-Barba M; Sanz GF; Del Cañizo AC;
Cancer; 2011 Dec; 117(24):5529-37. PubMed ID: 21638279
[TBL] [Abstract][Full Text] [Related]
17. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions.
Stanworth SJ; Dyer C; Choo L; Bakrania L; Copplestone A; Llewelyn C; Norfolk D; Powter G; Littlewood T; Wood EM; Murphy MF;
Transfus Med Rev; 2010 Jul; 24(3):163-71. PubMed ID: 20656185
[TBL] [Abstract][Full Text] [Related]
18. Rationale and design of platelet transfusions in haematopoietic stem cell transplantation: the PATH pilot study.
Tay J; Allan D; Beattie S; Bredeson C; Fergusson D; Maze D; Sabloff M; Thavorn K; Tinmouth A
BMJ Open; 2016 Oct; 6(10):e013483. PubMed ID: 27798034
[TBL] [Abstract][Full Text] [Related]
19. Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes.
Neukirchen J; Blum S; Kuendgen A; Strupp C; Aivado M; Haas R; Aul C; Gattermann N; Germing U
Eur J Haematol; 2009 Nov; 83(5):477-82. PubMed ID: 19548919
[TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial.
Kantarjian HM; Fenaux P; Sekeres MA; Szer J; Platzbecker U; Kuendgen A; Gaidano G; Wiktor-Jedrzejczak W; Carpenter N; Mehta B; Franklin J; Giagounidis A
Lancet Haematol; 2018 Mar; 5(3):e117-e126. PubMed ID: 29396092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
